A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
This Phase II, multicenter, randomized, double-blind, placebo-controlled trial was designed to estimate the efficacy and characterize the safety of bevacizumab when combined with carboplatin + paclitaxel chemotherapy compared with carboplatin + paclitaxel chemotherapy alone in patients with previously untreated metastatic melanoma.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : bevacizumab
- drug : placebo
- drug : paclitaxel
- drug : carboplatin
Phase: Phase 2
Ages Eligible For Study:
- Signed Informed Consent Form - Age ? 18 years - Metastatic melanoma (Stage IV) - Histologically confirmed malignant melanoma with measurable or non-measurable disease - Ability and willingness to comply with study and follow-up procedures